ArticleScientific reports2026
Differences in red blood cell fatty acid profiles by type 2 diabetes status in early-stage chronic kidney disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemorheological Alterations as a Driver of Microangiopathy in Diabetic Kidney Disease-The Role of Erythrocyte.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRed blood cell (RBC) membrane fatty acid composition may reflect early metabolic disturbances linked to chronic kidney disease (CKD) and type 2 diabetes (T2D), offering insights into shared pathophysiological mechanisms. This study aimed to characterise RBC membrane fatty acid profiles in individuals with early-stage CKD, comparing those with and without T2D to identify disease-specific patterns.
methodsThe cross-sectional analysis comprised 893 participants (290 with T2D and 603 deemed at high risk of T2D by the African Diabetes Risk Score), aged ≥ 18 years, recruited from 16 communities in Cape Town, South Africa, between 2017 and 2019. RBC membrane fatty acids were extracted and analysed using gas chromatography. CKD was defined as an estimated glomerular filtration rate < 60 ml/min/1.73 m² and/or albumin-to-creatinine ratio > 3 mg/mmol.
resultsIn total, 25.9% presented with CKD, 36.1% with T2D, and 15.6% presented with comorbid CKD and T2D. A higher lipogenic index was associated with an increased odds of prevalent CKD [OR (95% CI): 2.73 (1.22-6.12); p = 0.015], with 18:2n-6 (linoleic acid) [OR (95% CI): 0.81 (0.67-0.99); p = 0.035], total n-6 polyunsaturated fatty acids (PUFA) [OR (95% CI): 0.86 (0.76-0.98); p = 0.025], and total PUFA [OR (95% CI): 0.88 (0.77-0.99); p = 0.041] associated with reduced odds of prevalent CKD, with the associations between the PUFAs modified by T2D status (interaction p < 0.070).
conclusionOur findings showed that comorbid CKD and T2D exacerbates changes in PUFAs, suggesting complex metabolic interactions. These fatty acids may be of clinical value adding to already existing biomarkers to improve early detection or monitoring of these diseases. Furthermore, promoting appropriately balanced dietary intake of n-6 and n-3 PUFAs, could support metabolic health, contributing to more personalized patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.